There is no difference in hepatic fibrosis rates of patients infected with hepatitis C virus and those co-infected with HIV

Some studies have suggested that human immunodeficiency virus (HIV) infection modifies the natural history of hepatitis C virus (HCV) infection, accelerating the progression of fibrosis and the development of cirrhosis. Our objective was to evaluate the fibrosis progression rate (FPR) in HCV/HIV-co-infected patients, and to identify factors that may influence it. HCV-mono-infected and HCV/HIV-co-infected patients with a known date of HCV infection (transfusion or injection drug use) and a liver biopsy were included. The FPR was defined as the ratio between the fibrosis stage (Metavir score) and the estimated length of infection in years and the result was reported as fibrosis units per year. The factors studied were gender, age at infection, consumption of alcohol, aminotransferase levels, histological activity grade, HCV genotype and viral load, CD4 cell count, HIV viral load, and the use of antiretroviral therapy. Sixty-five HCV-infected (group 1) and 53 HCV/HIV-co-infected (group 2) patients were evaluated over a period of 19 months. The mean FPR of groups 1 and 2 was 0.086 ± 0.074 and 0.109 ± 0.098 fibrosis units per year, respectively (P = 0.276). There was a correlation between length of HCV infection and stage of fibrosis in both groups. The age at infection, the aspartate aminotransferase level (r = 0.36) and the inflammatory activity grade were correlated with the FPR (P < 0.001). No difference in FPR was found between HCV-mono-infected and HCV/HIV-co-infected patients.

Simultaneous detection of the C282Y, H63D and S65C mutations in the hemochromatosis gene using quenched-FRET real-time PCR

Hereditary hemochromatosis (HH) is a common autosomal disorder of iron metabolism mainly affecting Caucasian populations. Three recurrent disease-associated mutations have been detected in the hemochromatosis gene (HFE): C282Y, H63D, and S65C. Although HH phenotype has been associated with all three mutations, C282Y is considered the most relevant mutation responsible for hemochromatosis. Clinical complications of HH include cirrhosis of the liver, congestive cardiac failure and cardiac arrhythmias, endocrine pancreatic disease, which can be prevented by early diagnosis and treatment. Therefore, a reliable genotyping method is required for presymptomatic diagnosis. We describe the simultaneous detection of the C282Y, H63D and S65C mutations in the hemochromatosis gene by real-time PCR followed by melting curve analysis using fluorescence resonance energy transfer (FRET) probes. The acceptor fluorophore may be replaced by a quencher, increasing multiplex possibilities. Real-time PCR results were compared to the results of sequencing and conventional PCR followed by restriction digestion and detection by agarose gel electrophoresis (PCR-RFLP). Genotypes from 80 individuals obtained both by the conventional PCR-RFLP method and quenched-FRET real-time PCR were in full agreement. Sequencing also confirmed the results obtained by the new method, which proved to be an accurate, rapid and cost-effective diagnostic assay. Our findings demonstrate the usefulness of real-time PCR for the simultaneous detection of mutations in the HFE gene, which allows a reduction of a significant amount of time in sample processing compared to the PCR-RFLP method, eliminates the use of toxic reagents, reduces the risk of contamination in the laboratory, and enables full process automation.

Does hepatocellular carcinoma in non-alcoholic steatohepatitis exist in cirrhotic and non-cirrhotic patients?

Non-alcoholic steatohepatitis (NASH) has been associated with hepatocellular carcinoma (HCC) often arising in histologically advanced disease when steatohepatitis is not active (cryptogenic cirrhosis). Our objective was to characterize patients with HCC and active, histologically defined steatohepatitis. Among 394 patients with HCC detected by ultrasound imaging over 8 years and staged by the Barcelona Clinic Liver Cancer (BCLC) criteria, we identified 7 cases (1.7%) with HCC occurring in the setting of active biopsy-proven NASH. All were negative for other liver diseases such as hepatitis C, hepatitis B, autoimmune hepatitis, Wilson disease, and hemochromatosis. The patients (4 males and 3 females, age 63 ± 13 years) were either overweight (4) or obese (3); 57% were diabetic and 28.5% had dyslipidemia. Cirrhosis was present in 6 of 7 patients, but 1 patient had well-differentiated HCC in the setting of NASH without cirrhosis (fibrosis stage 1) based on repeated liver biopsies, the absence of portal hypertension by clinical and radiographic evaluations and by direct surgical inspection. Among the cirrhotic patients, 71.4% were clinically staged as Child A and 14.2% as Child B. Tumor size ranged from 1.0 to 5.2 cm and 5 of 7 patients were classified as early stage; 46% of all nodules were hyper-echoic and 57% were <3 cm. HCC was well differentiated in 1/6 and moderately differentiated in 5/6. Alpha-fetoprotein was <100 ng/mL in all patients. HCC in patients with active steatohepatitis is often multifocal, may precede clinically advanced disease and occurs without diagnostic levels of alpha-fetoprotein. Importantly, HCC may occur in NASH in the absence of cirrhosis. More aggressive screening of NASH patients may be warranted.

Histone demethylase retinoblastoma binding protein 2 regulates the expression of α-smooth muscle actin and vimentin in cirrhotic livers

Liver cirrhosis is one of the most common diseases of Chinese patients. Herein, we report the high expression of a newly identified histone 3 lysine 4 demethylase, retinoblastoma binding protein 2 (RBP2), and its role in liver cirrhosis in humans. The siRNA knockdown of RBP2 expression in hepatic stellate cells (HSCs) reduced levels of α-smooth muscle actin (α-SMA) and vimentin and decreased the proliferation of HSCs; and overexpression of RBP2 increased α-SMA and vimentin levels. Treatment with transforming growth factor β (TGF-β) upregulated the expression of RBP2, α-SMA, and vimentin, and the siRNA knockdown of RBP2 expression attenuated TGF-β-mediated upregulation of α-SMA and vimentin expression and HSC proliferation. Furthermore, RBP2 was highly expressed in cirrhotic rat livers. Therefore, RBP2 may participate in the pathogenesis of liver cirrhosis by regulating the expression of α-SMA and vimentin. RBP2 may be a useful marker for the diagnosis and treatment of liver cirrhosis.

Occult hepatitis B virus infection in liver transplant patients in a Brazilian referral center

Estimates of occult hepatitis B virus (HBV) infection prevalence varies among different studies depending on the prevalence of HBV infection in the study population and on the sensitivity of the assay used to detect HBV DNA. We investigated the prevalence of occult HBV infection in cirrhotic patients undergoing liver transplantation in a Brazilian referral center. Frozen liver samples from 68 adults were analyzed using a nested polymerase chain reaction assay for HBV DNA. The specificity of the amplified HBV sequences was confirmed by direct sequencing of the amplicons. The patient population comprised 49 (72.1%) males and 19 (27.9%) females with a median age of 53 years (range=18-67 years). Occult HBV infection was diagnosed in three (4.4%) patients. The etiologies of the underlying chronic liver disease in these cases were alcohol abuse, HBV infection, and cryptogenic cirrhosis. Two of the patients with cryptic HBV infection also presented hepatocellular carcinoma. Markers of previous HBV infection were available in two patients with occult HBV infection and were negative in both. In conclusion, using a sensitive nested polymerase chain reaction assay to detect HBV DNA in frozen liver tissue, we found a low prevalence of occult HBV infection in cirrhotic patients undergoing liver transplant, probably due to the low prevalence of HBV infection in our population.

Changes in epidemiology of rotavirus in the Triângulo Mineiro region of Brazil: lack of two consecutive rotavirus seasons

Rotaviruses are the main cause of infantile acute diarrhea, and a monovalent (G1P[8]) vaccine against the virus was introduced into the Brazilian National Immunization Program for all infants in March 2006. The objectives of this study were to determine the rate and genotype distribution of rotavirus causing infantile diarrhea in the Triângulo Mineiro region of Brazil during 2011-2012 and to assess the impact of local vaccination. Fecal specimens were analyzed for detection and characterization of rotavirus using polyacrylamide gel electrophoresis, reverse transcription followed by polymerase chain reaction (PCR), and PCR-genotyping assays. Overall, rotavirus was diagnosed in 1.7% (6/348) of cases. Rotavirus positivity rates decreased 88% [95% confidence intervals (CI)=15.2, 98.3%; P=0.026] in 2011 and 78% (95%CI=30.6, 93.0%; P=0.007) in 2012 when compared with available data for baseline years (2005/2006) in Uberaba. In Uberlândia, reductions of 95.3% (95%CI=66.0, 99.4%; P=0.002) in 2011, and 94.2% (95%CI=56.4, 99.2%; P=0.004) in 2012 were also observed compared with data for 2008. The circulation of rotavirus G2P[4] strains decreased during the period under study, and strains related to the P[8] genotype reemerged in the region. This study showed a marked and sustained reduction of rotavirus-related cases, with a lack of rotavirus in the 2011 and 2012 seasons, suggesting a positive impact of the vaccination program.

Sorafenib prevents liver fibrosis in a non-alcoholic steatohepatitis (NASH) rodent model

Liver fibrosis occurring as an outcome of non-alcoholic steatohepatitis (NASH) can precede the development of cirrhosis. We investigated the effects of sorafenib in preventing liver fibrosis in a rodent model of NASH. Adult Sprague-Dawley rats were fed a choline-deficient high-fat diet and exposed to diethylnitrosamine for 6 weeks. The NASH group (n=10) received vehicle and the sorafenib group (n=10) received 2.5 mg·kg-1·day-1 by gavage. A control group (n=4) received only standard diet and vehicle. Following treatment, animals were sacrificed and liver tissue was collected for histologic examination, mRNA isolation, and analysis of mitochondrial function. Genes related to fibrosis (MMP9, TIMP1, TIMP2), oxidative stress (HSP60, HSP90, GST), and mitochondrial biogenesis (PGC1α) were evaluated by real-time quantitative polymerase chain reaction (RT-qPCR). Liver mitochondrial oxidation activity was measured by a polarographic method, and cytokines by enzyme-linked immunosorbent assay (ELISA). Sorafenib treatment restored mitochondrial function and reduced collagen deposition by nearly 63% compared to the NASH group. Sorafenib upregulated PGC1α and MMP9 and reduced TIMP1 and TIMP2 mRNA and IL-6 and IL-10 protein expression. There were no differences in HSP60, HSP90 and GST expression. Sorafenib modulated PGC1α expression, improved mitochondrial respiration and prevented collagen deposition. It may, therefore, be useful in the treatment of liver fibrosis in NASH.

薛院判醫案二十四種Xie yuan pan yi an er shi si zhong.Archives médicales du médecin impérial Xie.Nei ke.Médecine interne.

Contient : I十四經絡發揮Shi si jing luo fa hui.Examen des quatorze vaisseaux ; II難經本義Nan jing ben yi.Sens du Nan jing ; III本草發揮Ben cao fa hui.Traité de matière médicale ; IV平治會萃Ping zhi hui zui.Traité sur diverses maladies ; V家居醫錄內科摘要Jia ju yi lu nei ke zhe yao.Éléments de médecine interne ; VI明醫雜著Ming yi za zhu.Traités divers de médecins célèbres ; VII傷寒鈐法Shang han qian fa.Étude du traité de la fièvre typhoïde ; VIII敖氏外傷金鏡錄圖Ao shi wai shang jin jing lu tu.Traité de la langue dans la fièvre typhoïde ; IX原機啟微Yuan ji qi wei.Traité sur les maladies et les médicaments.You ke.Médecine infantile ; X保嬰撮要Bao ying tshoo yao.Traité général de médecine infantile ; XI錢氏小兒直（眞）訣Qian shi xiao er zhi (zhen) jue.Traité de médecine infantile ; XII陳氏小兒痘疹方論Chen shi xiao er dou zhen fang lun.Formules et traité pour la petite vérole chez les enfants ; XIII保嬰金鏡錄Bao ying jin jing lu.Traité de médecine infantile.Nü ke.Gynécologie ; XIV婦人良方Fu ren liang fang.Formules pour les maladies des femmes ; XV女科撮要Nü ke tshoo yao.Principes de gynécologie.Wai ke.Médecine externe ; XVI立齋外科發揮Li zhai wai ke fa hui.Examen de la médecine externe ; XVII外科心法Wai ke xin fa.Préceptes de médecine externe ; XVIII外科樞要Wai ke chu yao.Principes de médecine externe ; XIX外科精要Wai ke jing yao.Éléments de médecine externe ; XX癰疽神秘驗方Yong ju shen bi yan fang.Formules pour les furoncles ; XXI外科經驗方Wai ke jing yan fang.Formules éprouvées de médecine externe ; XXII正體類要Zheng ti lei yao.Exposé méthodique du corps humain ; XXIII口齒類要Kou chi lei yao.Exposé méthodique de la bouche et des dents ; XXIV癘瘍機要Li yang ji yao.Traité des ulcères

薛院判醫案二十四種Xie yuan pan yi an er shi si zhong.Archives médicales du médecin impérial Xie.Nei ke.Médecine interne.

Contient : I十四經絡發揮Shi si jing luo fa hui.Examen des quatorze vaisseaux ; II難經本義Nan jing ben yi.Sens du Nan jing ; III本草發揮Ben cao fa hui.Traité de matière médicale ; IV平治會萃Ping zhi hui zui.Traité sur diverses maladies ; V家居醫錄內科摘要Jia ju yi lu nei ke zhe yao.Éléments de médecine interne ; VI明醫雜著Ming yi za zhu.Traités divers de médecins célèbres ; VII傷寒鈐法Shang han qian fa.Étude du traité de la fièvre typhoïde ; VIII敖氏外傷金鏡錄圖Ao shi wai shang jin jing lu tu.Traité de la langue dans la fièvre typhoïde ; IX原機啟微Yuan ji qi wei.Traité sur les maladies et les médicaments.You ke.Médecine infantile ; X保嬰撮要Bao ying tshoo yao.Traité général de médecine infantile ; XI錢氏小兒直（眞）訣Qian shi xiao er zhi (zhen) jue.Traité de médecine infantile ; XII陳氏小兒痘疹方論Chen shi xiao er dou zhen fang lun.Formules et traité pour la petite vérole chez les enfants ; XIII保嬰金鏡錄Bao ying jin jing lu.Traité de médecine infantile.Nü ke.Gynécologie ; XIV婦人良方Fu ren liang fang.Formules pour les maladies des femmes ; XV女科撮要Nü ke tshoo yao.Principes de gynécologie.Wai ke.Médecine externe ; XVI立齋外科發揮Li zhai wai ke fa hui.Examen de la médecine externe ; XVII外科心法Wai ke xin fa.Préceptes de médecine externe ; XVIII外科樞要Wai ke chu yao.Principes de médecine externe ; XIX外科精要Wai ke jing yao.Éléments de médecine externe ; XX癰疽神秘驗方Yong ju shen bi yan fang.Formules pour les furoncles ; XXI外科經驗方Wai ke jing yan fang.Formules éprouvées de médecine externe ; XXII正體類要Zheng ti lei yao.Exposé méthodique du corps humain ; XXIII口齒類要Kou chi lei yao.Exposé méthodique de la bouche et des dents ; XXIV癘瘍機要Li yang ji yao.Traité des ulcères

Traité pratique des maladies des enfants du premier âge : avec 88 figures dans le texte / par le docteur G. Variot, médecin de l'hospice des Enfants-Assistés et de l'hôpital Notre-Dame-du-Perpétuel-Secours, chef des services de l'Institut de puériculture, président-fondateur du dispensaire Goutte de lait de Belleville ; avec la collaboration de MM. le docteur Pironneau, ancien interne des hôpitaux ; Émile Grandjean, interne à l'hospice des Enfants-Assistés

Comprend : Formulaire de thérapeutique infantile / par M. Pierre Lavialle, docteur ès sciences, professeur à la Faculté de pharmacie de Strasbourg

STRATEGIES FOR PREVENTION AND TREATMENT OF HEPATITIS C VIRUS INFECTION

Hepatitis C virus (HCV) is the causative agent of Hepatitis C, a serious global health problem which results in liver cirrhosis and hepatocellular carcinoma. Currently there is no effective treatment or vaccine against the virus. Therefore, development of a therapeutic vaccine is of paramount importance. In this project, three alternative approaches were used to control HCV including a DNA vaccine, a recombinant viral vaccine and RNA interference. The first approach was to test the effect of different promoters on the efficacy of a DNA vaccine against HCV. Plasmids encoding HCV-NS3 and E1 antigens were designed under three different promoters, adenoviral E1A, MLP, and CMV ie. The promoter effect on the antigen expression in 293 cells, as well as on the antibody level in immunized BALB/c mice, was evaluated. The results showed that the antigens were successfully expressed from all vectors. The CMV ie promoter induced the highest antigen expression and the highest antibody level. Second, the efficiency of a recombinant adenovirus vaccine encoding HCV-NS3 was compared to that of a HCV-NS3 plasmid vaccine. The results showed that the recombinant adenovirus vaccine induced higher antibody levels as compared to the plasmid vaccine. The relationship between the immune response and miRNA was also evaluated. The levels of mir-181, mir-155, mir-21 and mir-296 were quantified in the sera of immunized animals. mir-181 and mir-21 were found to be upregulated in animals injected with adenoviral vectors. Third, two recombinant adenoviruses encoding siRNAs targeting both the helicase and protease parts of the NS3 region were tested for their ability to inhibit NS3 expression. The results showed that the siRNA against protease was more effective in silencing the HCV-NS3 gene in a HCV replicon cell line. This result confirmed the efficiency of adenovirus for siRNA delivery. These results confirmed that CMV ie is optimum promoter for immune response induction. Adenovirus was shown to be an effective delivery vector for antigens or siRNAs. In addition, miRNAs were proved to be involved in the regulation of immune response.

Bettelheim, Tinbergen and Hall fonds, 1972-1981

Elizabeth Hall was a managing editor of Psychology Today, who on separate occasions interviewed Oxford ethologist Nikolaas Tinbergen (1907-1988) and psychologist Bruno Bettelheim (1903-1990). Her 1973 interview with Tinbergen, conducted at his vacation home in the Cumberland region of northern England, was published later that year in Psychology Today. She left the magazine in 1976 to run the journal Human Nature, but left this position in 1979. She continued to contribute articles to various magazines, but most notably to Psychology Today. Her interview with Bruno Bettelheim appeared in that magazine in 1981.

Relations entre les facteurs de risque maternels et l’indice de masse corporelle d’enfants québécois avec surcharge pondérale dans un hôpital de soins tertiaires

L’étiologie de l’obésité infantile est multifactorielle et complexe. Le patrimoine génétique tout comme l’environnement d’un enfant peuvent favoriser l’apparition d’un surplus de poids. C’est pourquoi plusieurs études se sont penchées sur le lien entre l’environnement familial et en particulier le rôle de la mère et le risque d’obésité chez l’enfant. L’objectif est de mieux comprendre quels sont les facteurs de risque maternels spécifiques à chaque population afin de mieux prévenir ce fléau. Ce projet a donc cherché à identifier quelles sont les relations entre les facteurs de risque maternels et l’indice de masse corporelle d’enfants québécois avec surcharge pondérale. Parmi les facteurs de risque étudiés, on note des liens entre le niveau de scolarité de la mère, son statut familial et son niveau d’insécurité alimentaire. Sur le plan cognitif et comportemental, le lien entre l’indice de masse corporelle (IMC) de l’enfant et la perception maternelle du poids de son enfant ainsi que le niveau de restriction alimentaire maternel ont également été analysés. Au total, 47 entrevues ont été complétées par téléphone auprès des mères d’enfants obèses ou en embonpoint grâce à un large questionnaire destiné à décrire le profil des familles consultant les cliniques externes du CHU Ste Justine. Les tests de Fisher pour les variables catégorielles, le test de T de comparaison des moyennes du Z-score de l’IMC des enfants ont permis d’effectuer les analyses statistiques. Les résultats obtenus démontrent qu’un lien existe entre le niveau de scolarité maternel et la présence d’insécurité alimentaire. De même, il a été possible de constater que les enfants avec une mère restrictive des apports alimentaires de leur enfant avaient un Z-score de l’IMC significativement plus élevé. Ces résultats suggèrent qu’il existe des liens entre le profil socio-économique et comportemental de la mère et le surplus de poids de l’enfant. Des tests auprès d’un plus large échantillon seront nécessaires afin de confirmer ces résultats, l’objectif étant, entre autres, de mieux cibler les enfants à risque d’embonpoint ou d’obésité et de mieux outiller les professionnels de la santé en contact avec ces familles.

L'impact de la Convention de la Baie-James et du Nord québécois sur la santé des Cris de l'Iiyiyiu Aschii

Objectif: La santé des Indiens inscrits est inférieure à celle des autres Canadiens et dévoile des écarts importants entre les différents groupes qui la composent. La nation crie de l’Iiyiyiu Aschii, signataire de la Convention de la Baie-James et du Nord québécois (CBJNQ), bénéficie à cet égard d’un état de santé supérieur à celui des autres Indiens inscrits. L’objectif de ce mémoire est d’examiner l’impact de la CBJNQ sur les déterminants sociaux et l’état de santé de ses signataires cris depuis son entrée en vigueur en 1977. Méthodologie : Des analyses comparatives entre les Cris de l’Iiyiyiu Aschii, les Indiens inscrits et les Canadiens ont permis de suivre l’évolution à travers le temps des différences socioéconomiques, d’habitudes de vie et d’état de santé de ces groupes. Résultats : Les Cris ont enregistré, comparativement aux autres groupes d’Indiens inscrits vivant sur une réserve, une plus grande amélioration de leurs déterminants socioéconomiques, une progression relativement limitée de leurs comportements à risque et une préservation à un niveau plus élevé de leurs pratiques traditionnelles. Les Cris ont également vu progresser plus rapidement leur espérance de vie à la naissance que les Canadiens, et leur mortalité infantile a connu une chute encore plus importante que celle enregistrée chez les Indiens inscrits sur réserve. Conclusion : La CBJNQ a vraisemblablement eu un impact significatif sur la santé des Cris de l’Iiyiyiu Aschii. Cette amélioration sanitaire s’explique notamment par la Convention qui a su mettre en place des structures politiques qui ont favorisé l’amélioration des déterminants sociaux et le développement de l’autonomie gouvernementale des Cris.